Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young

Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten van Mölken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
9 Downloads (Pure)


Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic test compared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life year of screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory test and genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.

Original languageEnglish
Pages (from-to)375-385
Number of pages11
JournalPersonalized Medicine
Issue number4
Publication statusE-pub ahead of print - 11 Sept 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.


Dive into the research topics of 'Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young'. Together they form a unique fingerprint.

Cite this